Providing a diverse range of perspectives from bullish to bearish, 8 analysts have published ratings on Pacira BioSciences (NASDAQ:PCRX) in the last three months. The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months. Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $17.75, a high estimate of $39.00, and a low estimate of $8.00. This current average has decreased by 44.53% from the previous average price target of $32.00. Investiga…